Vaxil Financial Statements From 2010 to 2024

VXL Stock  CAD 0.01  0.00  0.00%   
Vaxil Bio financial statements provide useful quarterly and yearly information to potential Vaxil Bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vaxil Bio financial statements helps investors assess Vaxil Bio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vaxil Bio's valuation are summarized below:
Market Capitalization
1.4 M
There are over one hundred nineteen available fundamental trend indicators for Vaxil Bio, which can be analyzed over time and compared to other ratios. All traders should should double-check Vaxil Bio's current fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 3.5 M in 2024, whereas Enterprise Value is likely to drop slightly above 1.1 M in 2024.
Check Vaxil Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxil Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 114, Selling And Marketing Expenses of 17.1 or Other Operating Expenses of 241, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.9. Vaxil financial statements analysis is a perfect complement when working with Vaxil Bio Valuation or Volatility modules.
  
This module can also supplement various Vaxil Bio Technical models . Check out the analysis of Vaxil Bio Correlation against competitors.

Vaxil Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets853.8 K976 K785.1 K
Slightly volatile
Other Current Liabilities80.7 K84.9 K181.5 K
Slightly volatile
Total Current Liabilities80.8 K85 K363.4 K
Slightly volatile
Accounts Payable80.7585.0161.5 K
Pretty Stable
Cash665.5 K938 K621.6 K
Slightly volatile
Cash And Short Term Investments665.5 K938 K621.6 K
Slightly volatile
Net Receivables21.4 K19 K18.8 K
Slightly volatile
Common Stock Shares Outstanding143.8 M137 M62.5 M
Slightly volatile
Liabilities And Stockholders Equity853.8 K976 K785.1 K
Slightly volatile
Other Current Assets36.138.032 K
Pretty Stable
Total Liabilities80.8 K85 K373 K
Slightly volatile
Total Current Assets723.9 K976 K676.2 K
Slightly volatile
Accumulated Other Comprehensive Income2.3 M4.2 MM
Slightly volatile
Common Stock11.7 M18.5 M9.6 M
Slightly volatile
Short and Long Term Debt Total7.7 K8.1 K13 K
Pretty Stable
Deferred Long Term Liabilities668.8 K752.4 K819.3 K
Slightly volatile
Short and Long Term Debt66.7 K70.2 K349.7 K
Slightly volatile
Short Term Debt8.8 K8.1 K9.1 K
Pretty Stable
Property Plant Equipment1.7 K1.8 K64.4 K
Slightly volatile
Short Term Investments0.80.90.98
Slightly volatile
Inventory11.9 K21.8 K13.3 K
Slightly volatile
Non Currrent Assets Other88 K85.5 K125.9 K
Slightly volatile
Non Current Liabilities Other67.2 K75.6 K82.3 K
Slightly volatile
Capital Stock15.5 M18.5 M12.8 M
Slightly volatile
Property Plant And Equipment Gross210 K191.7 K266.6 K
Slightly volatile

Vaxil Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative114120599.7 K
Very volatile
Selling And Marketing Expenses17.118.0K
Slightly volatile
Other Operating Expenses241254926.8 K
Very volatile
Cost Of Revenue1.7 K1.8 K38.6 K
Pretty Stable
Total Operating Expenses241254909.7 K
Very volatile
Research Development108114306.7 K
Slightly volatile
Interest IncomeKK9.8 K
Slightly volatile

Vaxil Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation19 K20 K93.3 K
Very volatile
End Period Cash Flow665.5 K938 K621.6 K
Slightly volatile
Begin Period Cash Flow1.6 M1.5 M651.2 K
Slightly volatile
Sale Purchase Of Stock128.2 K135 K853.8 K
Slightly volatile
Change To Netincome59.9 K63 K1.4 M
Slightly volatile
Change To Inventory255.6 K247.5 K313.4 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables407429123.3 K
Pretty Stable
Capex To Depreciation4.856.716.4878
Slightly volatile
Inventory Turnover0.00320.00370.004
Slightly volatile
Days Of Inventory On Hand71.9 K80.9 K88.1 K
Slightly volatile
Payables Turnover5.555.8410.5147
Pretty Stable
Average Inventory1.1 K1.2 K1.3 K
Slightly volatile
Cash Per Share0.00650.00680.6737
Slightly volatile
Days Payables Outstanding78.5682.6939.5 K
Pretty Stable
Income Quality2.322.20870.949
Slightly volatile
Net Debt To EBITDA3.9 K3.7 K509
Slightly volatile
Current Ratio12.0611.48243.4722
Slightly volatile
Graham Number5.0E-45.0E-41.1629
Slightly volatile
Debt To Equity0.150.140.1124
Slightly volatile
Capex Per Share0.00450.00480.0064
Slightly volatile
Average Receivables13.3 K15 K12.1 K
Very volatile
Days Of Payables Outstanding78.5682.6939.5 K
Pretty Stable
Ebt Per Ebit1.111.161.0237
Slightly volatile
Total Debt To Capitalization0.130.120.0974
Slightly volatile
Debt Equity Ratio0.150.140.1124
Slightly volatile
Quick Ratio12.0611.48243.47
Slightly volatile
Net Income Per E B T0.00110.00120.7276
Slightly volatile
Cash Ratio11.5911.03533.1438
Slightly volatile
Days Of Inventory Outstanding71.9 K80.9 K88.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.020.9472
Pretty Stable

Vaxil Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.5 M2.5 M4.5 M
Slightly volatile

Vaxil Fundamental Market Drivers

Cash And Short Term Investments938 K

About Vaxil Bio Financial Statements

Vaxil Bio investors use historical fundamental indicators, such as Vaxil Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxil Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue103.5 K87.9 K
Cost Of Revenue1.8 K1.7 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.